Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have newly diagnosed brain tumor.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain and Central Nervous System Tumors Neuroblastoma Retinoblastoma Sarcoma |
Biological: filgrastim Drug: carboplatin Drug: cisplatin Drug: cyclophosphamide Drug: etoposide Drug: leucovorin calcium Drug: methotrexate Drug: temozolomide Drug: thiotepa Drug: vincristine sulfate Procedure: autologous bone marrow transplantation Procedure: peripheral blood stem cell transplantation Radiation: radiation therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue |
Eligibility| Ages Eligible for Study: | up to 10 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Histologically confirmed malignant, newly diagnosed brain tumor
Regimen A:
Posterior fossa medulloblastoma/primitive neuroectodermal tumor (PNET):
- All stages, under 3 years at diagnosis OR
- High stage (local residual tumor postoperatively and/or neuraxis or extraneural dissemination), 3-10 years at diagnosis
Supratentorial PNET, pineoblastoma, cerebral neuroblastoma, ependymoblastoma, medulloepithelioma, medullomyoblastoma:
- All stages, under 10 years at diagnosis
Brainstem PNET:
- All stages, irrespective of extent of resection, under 10 years at diagnosis
Ependymoma or anaplastic ependymoma:
- All stages, any location (except primary spinal cord ependymoma), under 3 years at diagnosis OR
- Local residual tumor postoperatively and/or neuraxis dissemination, any location, 3-10 years at diagnosis
Supratentorial ependymoma:
- All stages, irrespective of extent of resection, under 10 years at diagnosis, excluding gross totally resected (confirmed by postoperative MRI) low grade ependymoma not invading the ventricular system
Metastatic retinoblastoma:
- Previously untreated (except for cryosurgery or laser surgery), under 10 years at presentation of metastatic disease
Primary atypical teratoid/rhabdoid tumors of the CNS:
- Under 10 years at diagnosis
Choroid plexus carcinoma:
- Incompletely resected, all sites, under 10 years at diagnosis
Regimen C:
Anaplastic astrocytoma, glioblastoma multiforme, anaplastic oligodendroglioma, anaplastic ganglioglioma, other anaplastic mixed gliomas:
- Under 10 years at diagnosis
Diffuse intrinsic pontine tumors:
- Unbiopsied, under 10 years at diagnosis
The following diagnoses are not eligible:
- Myxopapillary ependymoma of the spinal cord, low grade brainstem astrocytoma, primary CNS lymphoma or solid leukemic lesion (i.e., chloroma, granulocytic sarcoma), or primary CNS germ cell tumor
PATIENT CHARACTERISTICS:
Age:
- Under 10 at diagnosis
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin less than 1.5 mg/dL
- SGPT less than 2.5 times upper limit of normal
Renal:
- Creatinine clearance greater than 60 mL/min
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Prior corticosteroids allowed
- No concurrent corticosteroids for the sole purpose of antiemesis
Radiotherapy:
- No prior radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from prior surgery
Contacts and Locations| United States, Hawaii | |
| Cancer Research Center of Hawaii | |
| Honolulu, Hawaii, United States, 96813 | |
| United States, Maine | |
| Maine Children's Cancer Program | |
| Scarborough, Maine, United States, 04074-9308 | |
| United States, Michigan | |
| Spectrum Health and DeVos Children's Hospital | |
| Grand Rapids, Michigan, United States, 49503 | |
| United States, Nebraska | |
| Children's Hospital of Omaha | |
| Omaha, Nebraska, United States, 68114 | |
| United States, New Jersey | |
| Hackensack University Medical Center | |
| Hackensack, New Jersey, United States, 07601 | |
| United States, New York | |
| Albert Einstein Clinical Cancer Center | |
| Bronx, New York, United States, 10461 | |
| Winthrop University Hospital | |
| Mineola, New York, United States, 11501 | |
| Beth Israel Hospital North | |
| New York, New York, United States, 10128 | |
| Herbert Irving Comprehensive Cancer Center | |
| New York, New York, United States, 10032 | |
| Memorial Sloan-Kettering Cancer Center | |
| New York, New York, United States, 10021 | |
| NYU School of Medicine's Kaplan Comprehensive Cancer Center | |
| New York, New York, United States, 10016 | |
| State University of New York Health Sciences Center - Stony Brook | |
| Stony Brook, New York, United States, 11790-7775 | |
| State University of New York - Upstate Medical University | |
| Syracuse, New York, United States, 13210 | |
| United States, Ohio | |
| St. Vincent Mercy Medical Center | |
| Toledo, Ohio, United States, 43608 | |
| United States, Pennsylvania | |
| Milton S. Hershey Medical Center | |
| Hershey, Pennsylvania, United States, 17033-0850 | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Wisconsin | |
| University of Wisconsin Comprehensive Cancer Center | |
| Madison, Wisconsin, United States, 53792-6164 | |
| Argentina | |
| Children's Hospital | |
| Buenos Aires, Argentina, 1425 | |
| Canada, British Columbia | |
| British Columbia Children's Hospital | |
| Vancouver, British Columbia, Canada, V6H 3V4 | |
| Study Chair: | Jonathan L. Finlay, MB, ChB | New York University School of Medicine |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00003273 History of Changes |
| Other Study ID Numbers: | CDR0000066174, NYU-P9712, NCI-V98-1400 |
| Study First Received: | November 1, 1999 |
| Last Updated: | June 3, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by New York University School of Medicine:
|
childhood infratentorial ependymoma childhood supratentorial ependymoma localized resectable neuroblastoma regional neuroblastoma disseminated neuroblastoma stage 4S neuroblastoma extraocular retinoblastoma |
childhood choroid plexus tumor localized unresectable neuroblastoma previously untreated childhood rhabdomyosarcoma untreated childhood supratentorial primitive neuroectodermal tumor untreated childhood medulloblastoma newly diagnosed childhood ependymoma |
Additional relevant MeSH terms:
|
Brain Neoplasms Nervous System Neoplasms Neuroblastoma Retinoblastoma Central Nervous System Neoplasms Sarcoma Neoplasms by Site Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases Neuroectodermal Tumors, Primitive, Peripheral Neuroectodermal Tumors, Primitive Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Retinal Neoplasms Eye Neoplasms Eye Diseases Retinal Diseases Neoplasms, Connective and Soft Tissue Etoposide phosphate Temozolomide Cisplatin Cyclophosphamide Etoposide Methotrexate |
ClinicalTrials.gov processed this record on May 16, 2013